LYPHE GROUP launches today, bringing together a portfolio of leading companies in the medical cannabis industry, to transform access to cannabis-based medical products for patients with unmet needs.
The patient-led healthcare provider is building across European markets by providing key infrastructure and vital educational services to patients, doctors and the sector, led by experts in the industry.
Each LYPHE GROUP business shares its central goal: to pioneer patient access to safe and effective medical cannabis treatments.
LYPHE GROUP is comprised of the following industry leading organisations:
- The Academy of Medical Cannabis – Following its successful launch last November, the online learning platform is training and educating clinicians and healthcare professionals solely on the subject of medical cannabis. The Academy, directed by Professor Mike Barnes, educates to reduce the stigma of this treatment option within the medical community around the world, as well as equipping clinicians with the knowledge to provide patients with expert care. The Academy has a growing presence globally, in locations including UK, Italy, Germany, France, Portugal, Ireland, Brazil and New Zealand.
- The Medical Cannabis Clinics – The UK’s first chain of private clinics specialising in innovative cannabis-based medical therapies and transforming lives by giving patients with unmet medical needs local access to the medical cannabis treatment options they so desperately need. Private clinic chain expert, Richard North continues his leadership of the clinics as Managing Director.
- Astral Health – The first platform to facilitate the bulk importation of medical cannabis into the UK, with import licenses in place across multiple jurisdictions, and extensive distribution in live markets beyond LYPHE GROUP’s ecosystem. Pharmaceutical Executive and Market Access specialist, Robert Whitehouse sits as the Managing Director of Astral Health.
- Dispensary Green – The UK’s first online home-delivery pharmacy for medical cannabis that forms the perfect compliant and seamless link between patients’ prescriptions, and fulfilment. Led by Pharmacist superintendent, Chris Ashton as Managing Director.
Through its integrated ecosystem of portfolio companies, LYPHE GROUP is breaking down barriers for patient access to medical cannabis by offering an innovative, standardised and seamless delivery of cannabis medicines and care. Through each of its composite companies, the group is empowering the medical community to prescribe with confidence and deliver the best medical cannabis care from consultation to delivery.
LYPHE GROUP is led by Chief Executive, Dean Friday, who brings over 12 years’ experience as a senior executive driving growth in start-up businesses. Professor Mike Barnes also joins as both a board member and head of the Medical & Scientific Leadership Board as Chief Medical Officer. A consultant neurologist, trusted international medical cannabis expert and UK’s leading medical campaigner for patient access, Professor Mike Barnes brings a wealth of unparalleled knowledge to LYPHE GROUP. They are joined by Jonathan Nadler, LYPHE GROUP’s Chief Strategy Officer and Hannah Simon as Chief Operating Officer.
Hannah Deacon, tireless campaigner for UK access to medical cannabis for her young son Alfie Dingley and every patient in need, is Head of Patient Access. Hannah’s involvement in LYPHE GROUP signals the company’s unwavering commitment to place patient needs at the heart of everything it does.
Associate Professor of the Department of Agronomy at the University of Padova, Stefano Bona joins as LYPHE GROUP’s Chief Scientific Officer after 30 years of research into the agricultural science of medical herbs, crops and soils. Andy Davies serves as Public Health Strategy Advisor with a focus on the UK market.
The company is headquartered in London, UK.
Dean Friday, CEO at LYPHE GROUP, commented:
“The launch of LYPHE GROUP is a pioneering step forward that will open up the market for import and prescribing of medical cannabis, improving access for patients in need. From training healthcare professionals to help them embrace this innovation in medicine, to providing the infrastructure for importation and fulfilling prescriptions, LYPHE GROUP supports the entire process – from consultation to delivery.
“Our integrated business model will help combat the disjointed system that currently inhibits patient access.”
Hannah Deacon, Head of Patient Access at LYPHE GROUP, said:
“For many families like mine, medical cannabis is a lifeline and yet it continues to be exceptionally difficult for patients to gain access. LYPHE GROUP’s all-encompassing service is a game-changer for the industry and I’m proud to be a part of an organisation committed to driving change so that more people in need have the opportunity to access medicines with the potential to give them a better quality of life.”
Professor Mike Barnes, Chief Medical Officer at LYPHE GROUP, commented:
“The combined knowledge and expertise brought together under LYPHE GROUP is unparalleled. Our Medical & Scientific Leadership Board is comprised of world-leading clinicians and scientists and together with our educators, pharmacists and public policy experts, we are committed to opening up access and driving forward transformation in the industry for the benefit of patients.”
SOURCE LYPHE GROUP
SLANG Worldwide to Participate in Investor Events
Toronto, Ontario–(Newsfile Corp. – August 7, 2020) – SLANG Worldwide Inc. (CSE: SLNG), (“SLANG” or the “Company“), a leading global cannabis consumer packaged goods (CPG) company with a diversified portfolio of popular brands, today announced its participation in upcoming investor conferences.
August 12: Canaccord Genuity 40th Annual Growth Conference
SLANG CEO Chris Driessen will present at 10:00am EDT and be available for investor meetings, along with other members of the executive team.
August 18: Benzinga Virtual Cannabis Capital Conference
SLANG CEO Chris Driessen will participate in a fireside chat at 1:05pm EDT titled “Adaptability in Business – When and Where to Apply Capital or Pull it Back.”
Mr. Driessen has also joined the Benzinga Cannabis Advisory Council, comprised of thought leaders from different segments in the industry who come together to share their knowledge, connections and expertise with the Benzinga community.
The Company will post details of these and other events on its website, including links to any available webcasts, when they become available. Investors who wish to receive SLANG news releases, monthly newsletters and other information are encouraged to subscribe to the Company’s investor email list though its website.
Media and Investor inquiries
About SLANG Worldwide Inc.
SLANG Worldwide Inc. is a global leader in the cannabis CPG sector with a diversified portfolio of popular brands distributed across the United States. The Company specializes in acquiring and developing market-proven regional brands as well as launching innovative new brands to seize global market opportunities. SLANG is listed on the Canadian Securities Exchange under the ticker symbol SLNG. For more information, please visit www.slangww.com.
This news release contains statements that constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur.
Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management of SLANG at this time, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that could cause actual results to differ materially from those expressed or implied in such statements. Investors are cautioned not to put undue reliance on forward-looking statements. Applicable risks and uncertainties include, but are not limited to regulatory risks, risks related to the COVID-19 global pandemic, changes in laws, resolutions and guidelines, market risks, concentration risks, operating history, competition, the risks associated with international and foreign operations and the other risks identified under the headings “Risk Factors” in SLANG’s final long form prospectus dated January 17, 2019 and “Risks and Uncertainties” in the management discussion and analysis for the year ended December 31, 2019 and three months ended March 31, 2020, each as filed on SEDAR at www.sedar.com. SLANG is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61312
PAOG CEO Interview: Cannabis Pharmaceutical Development; Acquired Revenue; Updated Financials; Why PPS Is Undervalued and Timing of Anticipated Correction
Sandusky, Ohio–(Newsfile Corp. – August 7, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced an interview of CEO James C. DiPrima on MoneyTV with Donald Baillargeon. The interview is available on the MoneyTV website discussing new cannabis pharmaceutical developments, a recently acquired revenue stream, upcoming financial reports bringing the company current with OTC Markets and discussing why the current price per share (PPS) of PAOG is undervalued and what event is anticipated to correct the valuation . Mr. DiPrima also appeared on MoneyTV last week following PAOG’s acquisition of two medical cannabis companies.
PAOG New Logo
To view an enhanced version of this graphic, please visit:
Mr. DiPrima discusses PAOG’s partnership with a Contract Research Organization (CRO) and a formal agreement in the works to advance an Investigational New Drug Application (IND) to ultimately achieve Food and Drug Administration (FDA) approval for RespRx (one of the two acquisitions executed by PAOG last week) as a COPD treatment.
Based on positive results from an informal trial of RexpRx with 25 COVID-19 patients, PAOG also plans to make Coronavirus Treatment Acceleration Program (CTAP) application after entering into a CRO agreement.
The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled, “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”
Mr. DiPrima confirms a recently published new PAOG website and the coming publication of PAOG’s financial reports. He further confirms the company now has a revenue base with the acquisition of a cannabis cultivation operation from Puration, Inc. (PURA). Mr. DiPrima concludes the interview with a discussion of why he believes the PPS is undervalued and that he anticipates a PPS correction when the PAOG financials are published.
MoneyTV with Donald Baillargeon is the internationally syndicated television program all about money and what makes it happen, featuring informative interviews with company CEOs and executives, providing insights into their operations and outlooks for their futures. MoneyTV is seen in over 200 million TV households in more than 75 countries.
The MoneyTV Interview is available at www.moneytv.net and will be syndicated across multiple channels and platforms.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61293
PURA Announces Dividend Declaration Date and Anticipated Date of Record
Dallas, Texas–(Newsfile Corp. – August 7, 2020) – Puration, Inc. (OTC Pink: PURA) today announced plans for a formal declaration of a dividend distribution this coming Monday, August 10, 2020. The dividend declaration is expected to be announced the following day, on Tuesday, August 11, 2020. The plan is for the dividend distribution date of record, or the day on which a shareholder must own stock to be eligible for the dividend to promptly follow the declaration date. The declaration date is subject to regulatory approval and the specific date will be released accordingly. The plan is also to pay the dividend promptly. The payment execution is subject to the payment process which involves the transfer agent(s) for the distributed stock and the broker network.
The planned dividend distribution to PURA shareholders results from the recent sale of PURA’s cannabis cultivation operation to PAO Group, Inc. (OTC Pink: PAOG).
The cannabis cultivation operation was sold last week in exchange for PAOG common stock. The stock is slated to be distributed to PURA shareholders in a dividend distribution. The planned distribution ratio is 1 for 1. Accordingly, PURA shareholders will receive one share of PAOG stock in exchange for every PURA share held.
For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/61295
Cannabis4 weeks ago
Medical Cannabis Market Size, Share, Growth Analysis, Global Trends, Industry Overview, Regional Forecast by 2027|Top Leaders-Aurora Cannabis, Aphria Medical Cannabis, MedReleaf Corp, Medical Marijuana: Says DBMR Analyst
Cannabis4 weeks ago
GenTech Secures Brand New Facility to Accommodate their Logistical Demands Associated with Accelerating SINFIT & SECRET JAVA Product Sales
Cannabis3 weeks ago
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Unveils World’s First COVID-19 Rapid Diagnostic Test for Neutralizing Antibodies and Files Pre-Emergency Use Authorization
Cannabis3 weeks ago
Relay Medical and Fio Corporation Extend MOU Agreement for Collaboration on a Rapid Diagnostic Testing Platform
Cannabis4 weeks ago
Nass Valley Gateway Ltd Announces It Will File Its 2019 EOY Audited Financials and 2019 Annual MD&A Reports by July 15th, 2020, and Within the 30-Day Extension Granted by the BCSC
Cannabis4 weeks ago
Leviathan Cannabis Provides Update on Tennessee Operations and Announces Name Change to Leviathan Natural Products Inc.
Cannabis4 weeks ago
Hemp, Inc. Praises The Advancement of Industrial Hemp Legalization in Hawaii
Cannabis3 weeks ago
Hemp, Inc. Praises USDA’s Recent Approval of Hemp Regulatory Plans for Minnesota, Tennessee, and Puerto Rico